Regenxbio (RGNX) Misses Q3 EPS by 12c, Revenues Miss

Regenxbio (RGNX) Reports Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II

REGENXBIO Inc. (NASDAQ: RGNX) today announced financial results for the quarter ended September 30, 2018 and recent operational highlights, including updates from its ongoing clinical trials.

"We are pleased to have recently treated the first subject in the Phase I/II study of RGX-121 from our neurodegenerative disease franchise and to have presented a continuing positive profile for our potential one-time treatment of RGX-314 for wet AMD, demonstrating sustained protein expression levels at six months. Furthermore, a major milestone was recently achieved through Novartis' announcement of the first worldwide marketing applications filed for a REGENXBIO... More

Regenxbio (RGNX), Abeona (ABEO) Announce Worldwide Exclusive Licenses for Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced a license agreement to REGENXBIO's NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known as neuronal ceroid lipofuscinosis... More

Abeona Therapeutics (ABEO) Reports Worldwide Exclusive Licenses with REGENXBIO (RGNX) for Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector

Abeona Therapeutics Inc.(NASDAQ: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, and REGENXBIO (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced a license agreement to REGENXBIOs NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known as neuronal ceroid lipofuscinosis type 1 (CLN1... More